HALIFAX, May 20 /PRNewswire/ - ImmunoVaccine Technologies Inc. (IVT), a vaccine development company, has announced a collaboration agreement with the National Research Council Institute for Biodiagnostics (NRC-IBD) Atlantic. This collaboration will develop new 3-D MRI technology to track the effect of IVT's DepoVax(TM) technology on reducing tumour growth.
"This research has the potential to deliver extremely sensitive MRI analysis, down to the individual cell level, and we will see, for the first time, our DepoVax(TM) formulation in action," remarked Dr. Marc Mansour, vice president R&D at IVT.
In pre-clinical studies, IVT has shown that DepoVax(TM) vaccines can eradicate cancerous tumors. This new research involves labeling liposomes, suspended in the DepoVax(TM) formulation, with iron-oxide nanoparticles. The 3-D MRI analysis will shed light on the activity of DepoVax(TM) in vivo, and allow the monitoring of tumor elimination in real time.
Current MRI techniques are well established in biomedical research. This research aims at developing highly sensitive and quantitative techniques for monitoring tumor progression and vaccine clearance in vivo.
"This collaboration means that NRC-IBD Atlantic will break new ground in developing novel MRI imaging techniques that will vastly improve the quality of information that may be acquired non-invasively," continued Mansour.
Most recently, ImmunoVaccine Technologies presented significant advancements in its therapeutic cancer, pandemic influenza and Hepatitis B vaccine applications at BIO 2009 international convention www.convention.bio.org.
ImmunoVaccine Technologies Inc., is a privately held, vaccine development
company. Through its own biotech research, patented DepoVax(TM) technology,
and collaborations with partners, I
|SOURCE ImmunoVaccine Technologies Inc.|
Copyright©2009 PR Newswire.
All rights reserved